ArticleCancer cell international2021
Ten-gene signature reveals the significance of clinical prognosis and immuno-correlation of osteosarcoma and study on novel skeleton inhibitors regarding MMP9.
Article in Cancer cell international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 27 citations in OpenAlex.
- Single-cell analysis identifies a tumor-specific T-cell metabolic signature: prognostic model and association with immunosuppressive microenvironment in ovarian cancer.Translational cancer research · 2026Article
- Multimodal deep learning for bone tumor diagnosis with clinical imaging, pathology, and blood biomarkers.Journal of bone oncology · 2025Article
- A multi-type programmed cell death gene signature predicts survival and reveals therapeutic targets in osteosarcoma.Discover oncology · 2025Article
- Single-cell transcriptional profiling in osteosarcoma and the effect of neoadjuvant chemotherapy on the tumor microenvironment.Journal of bone oncology · 2024Article
- Article
- New gene signature from the dominant infiltration immune cell type in osteosarcoma predicts overall survival.Scientific reports · 2023Article
- Ubiquitination-related biomarkers in metastatic melanoma patients and their roles in tumor microenvironment.Frontiers in oncology · 2023Article
- Global scientific trends on matrix metalloproteinase and osteosarcoma: A bibliometric and visualized analysis.Frontiers in oncology · 2023Article
- [RHPN2 is highly expressed in osteosarcoma cells to promote cell proliferation and migration and inhibit apoptosis].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022Article
- Article
- The role of SPI1-TYROBP-FCER1G network in oncogenesis and prognosis of osteosarcoma, and its association with immune infiltration.BMC cancer · 2022Article
- The bioinformatic approach identifiesFrontiers in oncology · 2022Article
- Innovative immune mechanisms and antioxidative therapies of intervertebral disc degeneration.Frontiers in bioengineering and biotechnology · 2022Review
- The Roles of Blood Lipid-Metabolism Genes in Immune Infiltration Could Promote the Development of IDD.Frontiers in cell and developmental biology · 2022Article
- High-Throughput Sequencing Reveals CXCR4 and IGF1 Behave Different Roles in Weightlessness Osteoporosis.Stem cells international · 2022Article
- Identification of the Transcription Co-Factor-Related Gene Signature and Risk Score Model for Osteosarcoma.Frontiers in genetics · 2022Article
- Emerging Applications of Deep Learning in Bone Tumors: Current Advances and Challenges.Frontiers in oncology · 2022Review
- Selected by bioinformatics and molecular docking analysis, Dhea and 2-14,15-Eg are effective against cholangiocarcinoma.PloS one · 2022Article
- Revealing oxidative stress-related genes in osteoporosis and advanced structural biological study for novel natural material discovery regardingFrontiers in endocrinology · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 7 institutions in 1 country.
Funding
Abstract
objectivesThis study aimed to identify novel targets in the carcinogenesis, therapy and prognosis of osteosarcoma from genomic level, together with screening ideal lead compounds with potential inhibition regarding MMP-9.
methodsGene expression profiles from GSE12865, GSE14359, GSE33382, GSE36001 and GSE99671 were obtained respectively from GEO database. Differentially expressed genes were identified, and functional enrichment analysis, such as GO, KEGG, GSEA, PPI were performed to make a comprehensive understanding of the hub genes. Next, a series of high-precision computational techniques were conducted to screen potential lead compounds targeting MMP9, including virtual screening, ADME, toxicity prediction, and accurate docking analysis.
results10 genes, MMP9, CD74, SPP1, CXCL12, TYROBP, FCER1G, HCLS1, ARHGDIB, LAPTM5 and IGF1R were identified as hub genes in the initiation of osteosarcoma. Machine learning, multivariate Cox analysis, ssGSEA and survival analysis demonstrated that these genes had values in prognosis, immune-correlation and targeted treatment. Tow novel compounds, ZINC000072131515 and ZINC000004228235, were screened as potential inhibitor regarding MMP9, and they could bind to MMP9 with favorable interaction energy and high binding affinity. Meanwhile, they were precited to be efficient and safe drugs with low-ames mutagenicity, none weight evidence of carcinogenicity, as well as non-toxic with liver.
conclusionsThis study revealed the significance of 10-gene signature in the development of osteosarcoma. Besides, drug candidates identified in this study provided a solid basis on MMP9 inhibitors' development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.